Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Therapeutics, Inc. (NASDAQ: VVOS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions, Vivos uses its SEC reports to describe its business, device portfolio, acquisitions, financing activities and governance matters.
Through periodic reports such as Forms 10-K and 10-Q, investors can review detailed discussions of Vivos’ operations, including its Complete Airway Repositioning and/or Expansion (CARE) devices, DNA appliance, Vivos Guides, VidaSleep oral appliance and related clinical and commercial initiatives. These filings also explain the company’s strategy of acquiring or affiliating with sleep centers, such as The Sleep Center of Nevada, and its revised OSA provider management model that uses jointly owned management entities.
Current reports on Form 8-K and amendments (8-K/A) highlight specific material events, including the completion of acquisitions, integration updates for sleep centers, clinical data announcements, changes to at-the-market offering programs, and the scheduling or results of stockholder meetings. Proxy statements on Form DEF 14A provide additional detail on board composition, equity incentive plans and matters submitted to stockholders for approval.
On Stock Titan, these VVOS filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key sections, such as risk factor updates, acquisition terms, and descriptions of new management or affiliation agreements. Users can also monitor items like late-filing notifications on Form 12b-25 and other compliance-related submissions. Together, the filings and AI analysis offer a structured view of how Vivos reports its evolving sleep apnea device business and sleep center operations to regulators and investors.
Vivos Therapeutics, Inc. entered a Securities Purchase Agreement with V-Co Investors 3 LLC for a private PIPE Offering. The company issued 1,353,625 common shares, a Pre-Funded Warrant for 429,957 shares, and Series A and B Warrants for up to 1,783,582 shares each.
V-Co 3 paid $1.34 per PIPE Share and Pre-Funded Warrant Share with associated warrants, providing $850,000 in cash and converting $1,400,000 previously funded under a bridge note into the PIPE. The Common Stock Purchase Warrants are exercisable at $1.09 per share, while the Pre-Funded Warrant has a $0.0001 exercise price.
The Series A Warrant has a two-year term and the Series B Warrant a five-year term. Warrants include stock-based anti-dilution protection and beneficial ownership limits at 19.99%. Vivos must file a resale registration statement within 45 days and seek effectiveness within 90 days, keeping it effective for up to three years. The company will pay $50,000 of V-Co 3’s counsel fees.
Vivos Therapeutics, Inc. disclosed that V-Co Investors 3 LLC, a ten percent owner associated with Michael C. Skaff, made a series of open-market purchases on March 31, 2026. The entity bought 1,353,625 shares of common stock at $1.34 per share, plus pre-funded and Series A and B common stock warrants at the same price, covering a total of 5,350,746 securities including underlying common shares. A bridge promissory note of $1,400,000 was also converted into common stock based on $1.09 per share plus $0.25 per share under Nasdaq minimum price rules. The Pre-Funded Warrant has a term ending upon complete exercise, while the Series A and Series B warrants have exercise prices of $1.09 and expire on March 31, 2028 and March 31, 2031, respectively. Skaff and SP Manager LLC disclaim beneficial ownership except to the extent of their pecuniary interest.
V-CO Investors LLC, related investment entities, and Michael C. Skaff filed a Schedule 13D disclosing a significant stake in Vivos Therapeutics, Inc.. Through V-CO, V-Co 2, and V-Co 3, they directly hold a total of 2,696,123 common shares, representing 19.9% of the company’s common stock.
On March 31, 2026, V-Co 3 entered a private placement with Vivos, purchasing 1,353,625 shares of common stock at $1.34 per share as part of a $2.39 million subscription. V-Co 3 also received Series A and Series B warrants, each exercisable for up to 1,783,582 shares at $1.09 per share, and a pre-funded warrant for up to 429,957 shares at $0.0001 per share, all subject to a 19.99% ownership cap. The filing states the investment is for general working capital and that the investors’ purpose is primarily investment, while reserving the right to discuss strategy and governance with the company.
Vivos Therapeutics, Inc. notified the SEC that it cannot timely file its Form 10-K for the year ended December 31, 2025 and expects to use the Rule 12b-25 extension.
The company says additional time is needed to complete year-end financial statements and disclosures related to its 2025 acquisition of Prabhu-Lata K. Shete MDs, LTD. d/b/a The Sleep Center of Nevada (SCN). The filing states the company anticipates revenue increased by over 15% for 2025 and that sales, general and administrative expenses rose approximately 50%, contributing to a larger net loss versus 2024. The notification is signed by CFO Bradford Amman and dated March 31, 2026.
Vivos Therapeutics director Gregg C. Johnson filed an initial ownership report showing indirect beneficial ownership of 3,997 shares of Vivos Therapeutics common stock. These shares are held through Spite Family Holdings LP, meaning the position is reported as indirect rather than personally held in his own name.
Vivos Therapeutics, Inc. filed a resale registration covering 3,964,712 shares of common stock issuable upon exercise of two series of investor warrants. A five-year Series A warrant and a 24-month Series B warrant each allow purchase of up to 1,982,356 shares at an exercise price of $2.09 per share.
The company is not selling any shares in this offering and will not receive proceeds from selling stockholder resales, but may receive up to approximately $8.29 million if the warrants are exercised for cash. Vivos will bear registration costs, while the selling stockholder pays its own selling expenses. The registered shares may be sold from time to time on Nasdaq, where Vivos trades under the symbol VVOS.
Vivos Therapeutics, Inc. appointed Gregg C. E. Johnson as an independent director to its Board of Directors, effective February 4, 2026. He will also serve on the Board’s Compensation Committee.
Mr. Johnson will receive an annual non-employee director cash fee of $48,000, plus $5,000 for each Board committee membership, and is eligible for stock option awards under the company’s 2024 Equity Incentive Plan. He previously served as Vivos’ Secretary and as a director and has held senior roles in law, corporate compliance, capital markets and high-growth companies in Canada and the United States. The company states he has no family relationships with current directors or executives and no material interests in related-party transactions, and that there were no special arrangements or understandings behind his selection.
Vivos Therapeutics, Inc. entered a warrant inducement agreement with an institutional holder, leading to the cash exercise in full of three existing warrant series at a reduced exercise price of $2.34 per share, generating approximately $4.6 million in gross proceeds. In return, Vivos issued new Inducement Warrants: a five-year Series A and a 24‑month Series B, each to purchase up to 1,982,356 shares of common stock at an exercise price of $2.09 per share, for a total of 3,964,712 underlying shares. The company plans to use the net proceeds for working capital and general corporate purposes and must file a resale registration statement for the Inducement Warrant Shares by February 14, 2026. H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee, a 1.0% management fee, expense reimbursement, and warrants to purchase 138,765 shares at an exercise price of $2.925 per share.
Vivos Therapeutics, Inc. entered into an unsecured convertible promissory note with V-Co Investors 3 LLC for a maximum principal amount of up to $5,500,000. V-Co, an affiliate of an existing private equity investor and advisor, has already funded $900,000 under the note to provide advance funding ahead of a proposed equity financing of up to $5,500,000 that is expected to close by February 16, 2026, the Outside Date.
The maximum principal includes a 10% original issuance discount as a financing fee to V-Co. The note carries no interest unless an event of default occurs, in which case interest accrues at 15% per year. If the equity financing occurs before the Outside Date, all principal automatically converts, dollar-for-dollar, into the same equity issued in that financing; after the Outside Date, the company may repay outstanding principal and any accrued interest without penalty. The note was issued in a private placement relying on a Section 4(a)(2) exemption and is not registered under securities laws.
Vivos Therapeutics is registering 1,982,356 shares of common stock for resale by a single institutional holder, Armistice Capital, issuable upon exercise of three previously issued warrants from January 2023, November 2023 and February 2024. Vivos will not sell any shares in this offering and will not receive proceeds from resale, but could receive up to approximately $8,489,485 if the warrants are exercised for cash. As of January 12, 2026, 9,437,788 shares of common stock were outstanding. The company discloses significant additional outstanding warrants, notes that large future sales could pressure its share price and highlight risks of dilution, financing needs and stock price volatility as it pursues a new sleep-center–focused growth model.